Literature DB >> 29348805

Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.

Robert J Wilson1, Edgars Jecs1, Eric J Miller1, Huy H Nguyen1, Yesim A Tahirovic1, Valarie M Truax1, Michelle B Kim1, Katie M Kuo1, Tao Wang2, Chi Shing Sum2, Mary E Cvijic2, Anthony A Paiva2, Gretchen M Schroeder2, Lawrence J Wilson1, Dennis C Liotta1.   

Abstract

CXCR4 is the most common chemokine receptor expressed on the surface of many cancer cell types. In comparison to normal cells, cancer cells overexpress CXCR4, which correlates with cancer cell metastasis, angiogenesis, and tumor growth. CXCR4 antagonists can potentially diminish the viability of cancer cells by interfering with CXCL12-mediated pro-survival signaling and by inhibiting chemotaxis. Herein, we describe a series of CXCR4 antagonists that are derived from (S)-5,6,7,8-tetrahydroquinolin-8-amine that has prevailed in the literature. This series removes the rigidity and chirality of the tetrahydroquinoline providing 2-(aminomethyl)pyridine analogs, which are more readily accessible and exhibit improved liver microsomal stability. The medicinal chemistry strategy and biological properties are described.

Entities:  

Year:  2017        PMID: 29348805      PMCID: PMC5767887          DOI: 10.1021/acsmedchemlett.7b00381

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  17 in total

Review 1.  The bicyclam AMD3100 story.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2003-07       Impact factor: 84.694

2.  The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.

Authors:  Renee M Mosi; Virginia Anastassova; Jennifer Cox; Marilyn C Darkes; Stefan R Idzan; Jean Labrecque; Gloria Lau; Kim L Nelson; Ketan Patel; Zefferino Santucci; Rebecca S Y Wong; Renato T Skerlj; Gary J Bridger; Dana Huskens; Dominique Schols; Simon P Fricker
Journal:  Biochem Pharmacol       Date:  2011-11-28       Impact factor: 5.858

Review 3.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

Review 4.  CXCR4 and CCR7: Two eligible targets in targeted cancer therapy.

Authors:  Mohammad Amir Mishan; Naghmeh Ahmadiankia; Ahmad Reza Bahrami
Journal:  Cell Biol Int       Date:  2016-07-22       Impact factor: 3.612

Review 5.  Homeostatic chemokine receptors and organ-specific metastasis.

Authors:  Albert Zlotnik; Amanda M Burkhardt; Bernhard Homey
Journal:  Nat Rev Immunol       Date:  2011-08-25       Impact factor: 53.106

Review 6.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

Review 7.  Chemokine signaling in cancer: one hump or two?

Authors:  Joshua B Rubin
Journal:  Semin Cancer Biol       Date:  2008-10-17       Impact factor: 15.707

8.  Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.

Authors:  Valarie M Truax; Huanyu Zhao; Brooke M Katzman; Anthony R Prosser; Ana A Alcaraz; Manohar T Saindane; Randy B Howard; Deborah Culver; Richard F Arrendale; Prahbakar R Gruddanti; Taylor J Evers; Michael G Natchus; James P Snyder; Dennis C Liotta; Lawrence J Wilson
Journal:  ACS Med Chem Lett       Date:  2013-09-05       Impact factor: 4.345

9.  Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers.

Authors:  Ying Jun Cao; Charles W Flexner; Shelia Dunaway; Jeong-Gun Park; Karin Klingman; Ilene Wiggins; Jeanne Conley; Christine Radebaugh; Angela D Kashuba; Ron MacFarland; Stephen Becker; Craig W Hendrix
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

Review 10.  Small molecule inhibitors of CXCR4.

Authors:  Bikash Debnath; Shili Xu; Fedora Grande; Antonio Garofalo; Nouri Neamati
Journal:  Theranostics       Date:  2013-01-15       Impact factor: 11.556

View more
  1 in total

1.  Synthesis and Anti-HIV Activity of a Novel Series of Isoquinoline-Based CXCR4 Antagonists.

Authors:  Mastaneh Safarnejad Shad; Sandra Claes; Eline Goffin; Tom Van Loy; Dominique Schols; Steven De Jonghe; Wim Dehaen
Journal:  Molecules       Date:  2021-10-18       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.